SAB Biotherapeutics, Inc. Stock Analysis & AI Score
SAB Biotherapeutics, Inc. (SABS) has an ST Score of 54.7 (B-), driven by its Profitability (A) and held back by its Growth (C-). Analysts rate it Buy with a $11.33 price target (+238.2% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
SAB Biotherapeutics, Inc. (SABS) has an ST Score of 54.7 (B-), driven by its Profitability (A) and held back by its Growth (C-). Analysts rate it Buy with a $11.33 price target (+238.2% upside).
- Strongest
- ProfitabilityA
- Weakest
- GrowthC-
All factor grades
- ProfitabilityA
- ForecastA
- Financial StrengthB+
- ValuationC+
- MomentumC+
- GrowthC-
- Piotroski1/9
Contact
SABS stock: frequently asked questions
What is SABS's ST Score?
SAB Biotherapeutics, Inc. (SABS) has an ST Score of 54.7 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is SABS a buy, hold, or sell?
Analysts rate SABS a Buy, with a price target of $11.33 (+238.2% vs the current price). Our ST Score grades it B- (54.7/100). The ST Score is a data-driven signal, not a recommendation.
What are SABS's factor grades?
Valuation C+, Profitability A, Financial Strength B+, Momentum C+, Growth C-, Forecast A.
What is SABS's valuation grade?
SAB Biotherapeutics, Inc. (SABS) earns a valuation grade of C+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is SABS's growth grade?
SAB Biotherapeutics, Inc. (SABS) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is SABS's profitability grade?
SAB Biotherapeutics, Inc. (SABS) earns a profitability grade of A, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is SABS's financial strength grade?
SAB Biotherapeutics, Inc. (SABS) earns a financial strength grade of B+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for SABS?
The average analyst price target for SAB Biotherapeutics, Inc. (SABS) is $11.33 from 8 analysts, which is +238.2% versus the recent price of $3.35.
What is SABS's Piotroski score?
SAB Biotherapeutics, Inc. (SABS) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.